- Home
- AQN vs SYRE Comparison
AQN vs SYRE Comparison
Compare AQN & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AQN | SYRE |
|---|---|---|
| Founded | 1988 | 2013 |
| Country | Canada | United States |
| Employees | 3786 | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7B | 4.0B |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | AQN | SYRE |
|---|---|---|
| Price | $6.30 | $71.99 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 12 |
| Target Price | $6.66 | ★ $85.08 |
| AVG Volume (30 Days) | ★ 3.8M | 1.2M |
| Earning Date | 05-08-2026 | 05-08-2026 |
| Dividend Yield | ★ 4.10% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $4.87 | N/A |
| Revenue Next Year | $5.02 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.27 | $12.29 |
| 52 Week High | $7.11 | $75.00 |
Technical Indicators
Market Signals| Indicator | AQN | SYRE |
|---|---|---|
| Relative Strength Index (RSI) | 49.37 | 73.71 |
| Support Level | $6.00 | $30.39 |
| Resistance Level | $6.34 | $75.00 |
| Average True Range (ATR) | 0.12 | 4.66 |
| MACD | 0.01 | 0.51 |
| Stochastic Oscillator | 43.33 | 87.77 |
Price Performance
Historical ComparisonAbout AQN Algonquin Power & Utilities Corp.
Algonquin Power & Utilities Corp is a Canada-based diversified international generation, transmission, and distribution company. The company's operations are organized across two business units: the Regulated Services Group, which owns and operates a portfolio of regulated electric, water distribution, and wastewater collection, and natural gas utility systems and transmission operations in the United States, Canada, Bermuda, and Chile; and the Hydro Group, which consists of hydroelectric-generating facilities located in Canada. It generates the majority of its revenue from the Regulated Services Group segment.
About SYRE Spyre Therapeutics Inc.
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.